SYNLOGIC, INC. Lease Obligation Incurred
SYNLOGIC, INC. (SYBX) reported Lease Obligation Incurred of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-29.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2023-03-29
- SYNLOGIC, INC. lease obligation incurred for the quarter ending 2021-12-31 was $0.00.
- SYNLOGIC, INC. lease obligation incurred for the quarter ending 2021-09-30 was $0.00.
- SYNLOGIC, INC. lease obligation incurred for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- SYNLOGIC, INC. lease obligation incurred for fiscal 2021 was $36.00K.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 6 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-29 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | $0.00 derived: sum of 2 quarters · filed 2023-03-29 | $36.00K 10-K · filed 2023-03-29 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $36.00K 10-Q · filed 2022-11-10 | ||
| 2021-06-30 | $36.00K 10-Q · filed 2022-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |